{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:39:48Z","timestamp":1778629188197,"version":"3.51.4"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Bupropion, a norepinephrine and dopamine reuptake inhibitor, is FDA\u2010approved for depression and smoking cessation but not for anxiety disorders. Its role in patients with comorbid depression and anxiety remains debated. This review examines bupropion's potential anxiolytic and\/or anxiogenic effects. Clinical trials suggest bupropion may reduce anxiety symptoms in depressed patients, showing comparable efficacy to SSRIs and SNRIs in mild to moderate anxiety. However, its stimulating properties can also provoke anxiety, particularly at higher doses. While some studies indicate no significant difference in anxiolytic efficacy between bupropion and serotonergic antidepressants, others suggest SSRIs may be preferable for severe depression with anxious distress. Emerging data hint at potential benefits for generalized and social anxiety disorders, though findings remain inconclusive. Given its mixed effects, a cautious approach is recommended. Initiating treatment at lower doses and monitoring for anxiogenic symptoms can help optimize outcomes. Further research is needed to clarify bupropion's potential role in anxiety management and its comparative efficacy against standard treatments.<\/jats:p>","DOI":"10.1002\/hup.70018","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:16:36Z","timestamp":1758089796000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Bupropion and Anxiety: A Brief Review"],"prefix":"10.1002","volume":"40","author":[{"given":"Sean E.","family":"Oldak","sequence":"first","affiliation":[{"name":"Department of Psychiatry at Brigham and Women's Hospital Dana Farber Cancer Institute Harvard Medical School  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Maristany","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v04n0110a"},{"issue":"1","key":"e_1_2_14_3_1","first-page":"46","article-title":"A Pilot Controlled Trial of Bupropion ER versus Escitalopram in Generalized Anxiety Disorder","volume":"41","author":"Bystritsky A.","year":"2008","journal-title":"Psychopharmacology Bulletin"},{"key":"e_1_2_14_4_1","unstructured":"Psych Central 2023 Can Wellbutrin Cause Anxiety and Panic Attacks?"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714\u2010199108000\u201000023"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2017.03.010"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v69n0812"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2007.05.012"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316629071"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001658"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010004\u20101965\u20109"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0165\u20100327(00)00250\u20100"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893\u2010133X(00)00249\u20109"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.23.2.jnpe47"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v62n1005"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v66n0510"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.70018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:33:32Z","timestamp":1758983612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.70018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/hup.70018"],"URL":"https:\/\/doi.org\/10.1002\/hup.70018","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70018"}}